F. Broly

发表

Targeting the DNM3OS / miR-199a~214 cluster for the treatment of fibroproliferative diseases

C. Marquette, S. Leroy, S. Bellusci, 2018, bioRxiv.

Ethnic differences in the distribution of CYP3A5 gene polymorphisms

J. Lo-Guidice, B. Lacarelle, M. Lhermitte, 2006, Xenobiotica; the fate of foreign compounds in biological systems.

Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients

M. Lhermitte, A. Niang, A. Touré, 2016, Toxicology reports.

Five novel natural allelic variants—951A>C, 1042G>A (D348N), 1156A>T (I386F), 1217G>A (C406Y) and 1291C>T (C431Y)—of the human CYP1A2 gene in a French Caucasian population

J. Lafitte, J. Lo-Guidice, C. Cauffiez, 2001, Human mutation.

Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes.

C. Libersa, M. Lhermitte, F. Broly, 1990, Biochemical pharmacology.

Interaction of propafenone and mexiletine.

C. Libersa, M. Lhermitte, F. Broly, 1993, Journal of the American College of Cardiology.

Mitochondrial myopathy caused by arsenic trioxide therapy.

L. Fornecker, A. Echaniz-Laguna, B. Mousson de Camaret, 2012, Blood.

Identification of genetic variants in the human thromboxane synthase gene (CYP5A1).

J. Lo-Guidice, C. Libersa, M. Lhermitte, 2001, Mutation research.

An ADHD 6-year-old child ultrarapid metabolizer for CYP2D6.

C. Barthélémy, F. Bonnet-Brilhault, R. Blanc, 2006, Journal of clinical psychopharmacology.

Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine.

V. Baudouin, C. Loirat, F. Broly, 2001, British journal of clinical pharmacology.

Stereoselective Hydroxylation of Mexiletine in Human Liver Microsomes: Implication of P450IID6− A Preliminary Report

C. Libersa, M. Lhermitte, F. Broly, 1993, Journal of cardiovascular pharmacology.

The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.

C. Libersa, M. Lhermitte, F. Broly, 1991, British journal of clinical pharmacology.

Single-dose quinidine treatment inhibits mexiletine oxidation in extensive metabolizers of debrisoquine.

C. Libersa, M. Lhermitte, F. Broly, 1991, Life sciences.

Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy.

B. Bonaz, R. Modigliani, P. Marteau, 2000, Gastroenterology.

Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping.

M. Kosel, P. Baumann, C. Eap, 1998, Pharmacopsychiatry.

ITPA genotyping test does not improve detection of Crohn’s disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression

C. Libersa, J. Colombel, D. Allorge, 2005, Gut.

High-performance liquid chromatographic assay for mexiletine hydroxylation in microsomes of human liver.

C. Libersa, M. Lhermitte, F. Broly, 1988, Journal of chromatography.

Characterisation of novel defective thiopurine S-methyltransferase allelic variants.

M. Loriot, P. Chavatte, J. Lo-Guidice, 2008, Biochemical pharmacology.

Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver.

P. Bechtel, C. Libersa, M. Lhermitte, 1989, British journal of clinical pharmacology.

A high performance liquid chromatographic method for the quantitation of flecainide in plasma.

M. Lhermitte, R. Houssin, F. Broly, 1991, Biomedical chromatography : BMC.

In-vitro analysis of the contribution of CYP2D6.35 to ultra-rapid metabolism.

G. Tucker, J. Lo-Guidice, G. Hayhurst, 2001, Pharmacogenetics.

Mexiletine metabolism in vitro by human liver.

C. Libersa, M. Lhermitte, F. Broly, 1990, Drug metabolism and disposition: the biological fate of chemicals.

Study of NAT2 genetic polymorphism in West African subjects: example of an healthy non-smoker Senegalese population

M. Lhermitte, A. Touré, D. Allorge, 2012, Molecular Biology Reports.

Genetic polymorphism of cytochrome P450 2D6 in idiopathic Parkinson disease and diffuse Lewy body disease.

A. Destée, R. Bordet, C. Libersa, 1994, Clinical neuropharmacology.

Molecular analysis of the N-acetyltransferase 1 gene (NAT1*) using polymerase chain reaction-restriction fragment-single strand conformation polymorphism assay.

J. Lo-Guidice, D. Allorge, D. Chevalier, 2000, Pharmacogenetics.

[Molecular pharmacogenetics in hospital laboratories in France: current data and future prospects].

M. Loriot, P. Beaune, P. Marquet, 2007, Annales pharmaceutiques francaises.

Genetic polymorphisms of Glycine N-acyltransferase (GLYAT) in a French Caucasian population

C. L. Lino Cardenas, J. Lo-Guidice, C. Cauffiez, 2010, Xenobiotica; the fate of foreign compounds in biological systems.

Thiopurine S-methyltransferase deficiency associated with a novel mutation.

J. Colombel, J. Jouet, A. Cortot, 2010, Inflammatory bowel diseases.

CYP2F1 genetic polymorphism: Identification of interethnic variations

J. Lo-Guidice, C. Cauffiez, F. Migot-Nabias, 2007, Xenobiotica; the fate of foreign compounds in biological systems.

A rare G2061 insertion affecting the open reading frame of CYP2D6 and responsible for the poor metabolizer phenotype.

S. Ellis, F. Broly, Geoffrey T. Tucker, 1999, Pharmacogenetics.